NGM Stock Price, NGM Biopharmaceuticals Quote, Chart

Market Summary

USD1.54

Delayed

NGM Stock Price

View Fullscreen

NGM RSI Chart

NGM Valuation

Market Cap

128.5M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

29.26

EV/EBITDA

-0.52

Price/Free Cashflow

-0.97

NGM Price/Sales (Trailing)

NGM Profitability

EBT Margin

-3240.58%

Return on Equity

-95.79%

Return on Assets

-84.31%

Free Cashflow Yield

-102.86%

NGM Fundamentals

NGM Revenue

Revenue (TTM)

4.4M

Rev. Growth (Yr)

-98.96%

Rev. Growth (Qtr)

-67.61%

NGM Earnings

Earnings (TTM)

-142.4M

Earnings Growth (Yr)

24.06%

Earnings Growth (Qtr)

3.91%

Breaking Down NGM Revenue

Last 7 days

-3.1%

Last 30 days

1.3%

Last 90 days

14.9%

Trailing 12 Months

-59.8%

How does NGM drawdown profile look like?

NGM Financial Health

Current Ratio

7.79

NGM Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

-1.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	36.6M	29.7M	22.4M	4.4M
2022	77.3M	68.8M	58.1M	55.3M
2021	84.6M	81.6M	76.7M	77.9M
2020	102.4M	96.8M	98.7M	87.4M
2019	115.6M	118.8M	119.6M	103.5M
2018	85.0M	92.9M	100.8M	108.7M
2017	0	0	0	77.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NGM Biopharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	rieflin william jl	sold	-	-	-5,172	-
Apr 05, 2024	tcg opportunity iii gp, llc	acquired	-	-	1,000	-
Apr 05, 2024	column group gp, lp	acquired	-	-	1,000	-
Apr 05, 2024	tcg opportunity iii gp, llc	back to issuer	-	-	-949,862	-
Apr 05, 2024	pierce valerie l	sold	-	-	-26,458	see remarks
Apr 05, 2024	column group l p	back to issuer	-	-	-8,291,310	-
Apr 05, 2024	column group gp, lp	back to issuer	-	-	-8,291,310	-
Apr 05, 2024	tcg opportunity iii gp, llc	back to issuer	-	-	-11,103,300	-
Apr 05, 2024	column group gp, lp	back to issuer	-	-	-949,862	-
Apr 05, 2024	viret jean-frederic	sold	-	-	-3,038	chief financial officer

Which funds bought or sold NGM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	1,000	1,000	-%
Apr 17, 2024	Clarius Group, LLC	added	1.15	19,935	42,790	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	7.13	55,672	112,311	0.01%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	74.02	204,180	296,109	0.01%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	21.00	550	-%
Apr 05, 2024	CWM, LLC	reduced	-99.07	-1,000	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-548	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.34	-574,455	2,379,920	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-19.02	-102,346	190,150	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-4,665	18,609	-%

Are Funds Buying or Selling NGM?

Are funds buying NGM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NGM

No. of Funds

Unveiling NGM Biopharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	column group l p	100%	1,000	SC 13D/A
Feb 26, 2024	column group l p	13.4%	11,103,333	SC 13D/A
Feb 14, 2024	ecor1 capital, llc	2.9%	2,385,873	SC 13G/A
Feb 13, 2024	vanguard group inc	3.35%	2,770,574	SC 13G/A
Dec 29, 2023	column group l p	13.4%	11,103,333	SC 13D/A
Oct 06, 2023	blackrock inc.	4.6%	3,839,879	SC 13G/A
Feb 13, 2023	rho ventures v, l.p.	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.49%	4,489,149	SC 13G
Feb 03, 2023	blackrock inc.	5.1%	4,158,643	SC 13G
Oct 28, 2022	ecor1 capital, llc	8.0%	6,435,518	SC 13G

Recent SEC filings of NGM Biopharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	15-12G	15-12G
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading

Peers (Alternatives to NGM Biopharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

NGM Biopharmaceuticals Inc News

Latest updates

NGM Biopharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-67.6%	188,500	582,000	1,423,000	2,200,000	18,181,000	7,911,000	8,293,000	20,948,000	20,959,000	18,575,000	16,773,000	21,575,000	19,767,000	23,482,000	19,755,000	24,364,000	31,083,000	21,568,000	25,341,000	25,552,000	47,119,000
Operating Expenses	-5.6%	29,828,000	31,613,000	41,998,000	52,441,000	56,478,000	56,215,000	55,360,000	53,529,000	48,183,000	47,581,000	53,393,000	49,420,000	47,440,000	53,439,000	45,288,000	45,034,000	48,377,000	34,565,000	35,048,000	34,894,000	34,063,000
S&GA Expenses	-8.5%	7,938,000	8,671,000	9,647,000	11,584,000	9,756,000	10,109,000	9,927,000	10,723,000	9,454,000	8,867,000	9,823,000	8,721,000	7,380,000	6,460,000	6,794,000	6,595,000	6,423,000	5,612,000	6,229,000	5,367,000	5,122,000
R&D Expenses	-4.6%	21,890,000	22,942,000	32,351,000	40,857,000	46,722,000	46,106,000	45,433,000	42,806,000	38,729,000	38,714,000	43,570,000	40,699,000	40,060,000	46,979,000	38,494,000	38,439,000	41,954,000	28,953,000	28,819,000	29,527,000	28,941,000
EBITDA Margin	-Infinity%	-31.91	-	-	-	-	-	-1.67	-1.48	-1.47	-	-	-1.21	-1.17	-0.43	-0.44	-0.42	-0.41	0.00	0.00	-	-
EBT Margin	-Infinity%	-32.41	-	-	-	-	-	-1.75	-1.56	-1.55	-	-	-1.21	-1.17	-0.43	-0.44	-0.42	-0.41	0.00	0.00	-	-
Net Income	3.9%	-27,670,000	-28,797,000	-38,261,000	-47,647,000	-36,437,000	-47,261,000	-46,519,000	-32,450,000	-27,234,000	-28,865,000	-36,692,000	-27,544,000	-27,991,000	-29,765,000	-25,616,000	-19,115,000	-15,941,000	-10,917,000	-7,669,000	-8,268,000	14,165,000
Net Income Margin	-380.0%	-32.41	-6.75	-5.71	-4.86	-2.94	-2.64	-1.96	-1.62	-1.55	-1.58	-1.50	-1.31	-	-	-	-	-	-	-	-	-
Free Cashflow	15.5%	-22,963,000	-27,164,000	-40,248,000	-41,827,000	-30,404,000	-28,146,000	-50,151,000	-35,738,000	-18,335,000	-9,359,000	-23,310,000	-22,225,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.1%	169	192	221	259	307	336	337	360	402	416	423	446	329	326	347	361	380	391	397	232	246
Current Assets	-11.6%	156	177	204	243	289	316	319	338	379	396	403	426	308	302	323	338	355	364	368	199	215
Cash Equivalents	8.4%	56.00	51.00	53.00	68.00	73.00	105	65.00	111	153	147	99.00	148	149	255	251	259	247	305	267	50.00	59.00
Net PPE	-3.4%	7.00	7.00	8.00	8.00	8.00	8.00	8.00	9.00	10.00	11.00	13.00	14.00	15.00	16.00	17.00	18.00	19.00	20.00	22.00	23.00	24.00
Liabilities	-9.5%	20.00	22.00	28.00	38.00	48.00	50.00	45.00	49.00	67.00	62.00	50.00	46.00	49.00	49.00	46.00	42.00	50.00	51.00	51.00	56.00	59.00
Current Liabilities	-10.1%	20.00	22.00	28.00	38.00	48.00	49.00	43.00	45.00	61.00	58.00	45.00	40.00	43.00	38.00	34.00	28.00	40.00	40.00	39.00	43.00	41.00
Shareholder's Equity	-12.5%	149	170	192	221	260	286	292	311	336	354	373	400	280	277	301	319	331	339	346	-	-
Retained Earnings	-4.0%	-724	-696	-667	-629	-581	-545	-497	-451	-418	-391	-362	-326	-298	-270	-240	-215	-196	-180	-169	-161	-147
Additional Paid-In Capital	0.7%	873	866	860	850	841	832	791	763	755	746	736	726	579	547	542	534	527	519	515	42.00	39.00
Shares Outstanding	0.2%	83.00	83.00	83.00	82.00	82.00	79.00	79.00	78.00	77.00	77.00	77.00	76.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	147	-	-	-	699	-	-	-	755	-	-	-	457	-	-	-	0.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	15.5%	-22,963	-27,164	-40,248	-41,827	-30,404	-28,146	-50,151	-35,738	-18,335	-9,359	-23,310	-22,225	-20,040	-25,165	-19,181	-19,110	-14,601	-6,696	-7,777	-12,100	7,008
Share Based Compensation	-1.8%	6,296	6,410	7,476	8,537	8,772	7,689	8,102	7,820	6,579	6,365	6,716	6,582	4,184	4,049	3,723	3,695	3,616	3,089	3,552	2,605	2,410
Cashflow From Investing	1.2%	27,192	26,869	24,585	35,641	1,688	35,453	-15,966	-6,853	21,926	52,304	-28,724	-117,156	-114,531	28,541	8,119	26,873	-46,390	43,622	48,998	2,493	3,482
Cashflow From Financing	-	111	-	1,385	279	723	33,218	19,624	668	2,378	3,478	3,324	140,477	27,612	908	3,427	3,591	3,573	643	176,538	-3.00	-1,058
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

NGM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Related party revenue	$ 4,417	$ 55,333	$ 77,882
Operating expenses:
Research and development	118,040	181,067	161,712
General and administrative	37,840	40,515	36,865
Total operating expenses	155,880	221,582	198,577
Loss from operations	(151,463)	(166,249)	(120,695)
Interest income, net	9,322	3,714	420
Other expense, net	(234)	(132)	(60)
Net loss	$ (142,375)	$ (162,667)	$ (120,335)
Net loss per share, basic (in dollars per share)	$ (1.73)	$ (2.03)	$ (1.56)
Net loss per share, diluted (in dollars per share)	$ (1.73)	$ (2.03)	$ (1.56)
Weighted average shares used to compute net loss per share, basic (in shares)	82,496,000	79,950,000	77,085,000
Weighted average shares used to compute net loss per share, diluted (in shares)	82,496,000	79,950,000	77,085,000

NGM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 55,816	$ 73,456
Short-term marketable securities	88,369	198,036
Prepaid expenses and other current assets	9,202	9,787
Restricted cash	2,999	0
Total current assets	156,444	288,859
Property and equipment, net	7,033	8,496
Operating lease right-of-use asset	0	2,096
Restricted cash	2,455	3,954
Other non-current assets	2,936	3,997
Total assets	168,868	307,402
Current liabilities:
Accounts payable	2,982	8,453
Accrued liabilities	17,099	33,638
Operating lease liability, current	0	5,385
Contract liabilities	0	366
Total current liabilities	20,081	47,842
Other non-current liabilities	149	0
Total liabilities	20,230	47,842
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued or outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, $0.001 par value; 400,000 shares authorized; 82,907 and 81,885 shares issued and outstanding as of December 31, 2023 and 2022, respectively	83	82
Additional paid-in capital	872,545	841,413
Accumulated other comprehensive income (loss)	18	(302)
Accumulated deficit	(724,008)	(581,633)
Total stockholders' equity	148,638	259,560
Total liabilities and stockholders' equity	168,868	307,402
Related Party
Current assets:
Related party receivable from collaboration	$ 58	$ 7,580

About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

CEO	Dr. David J. Woodhouse Ph.D.
WEBSITE	ngmbio.com
INDUSTRY	Biotechnology
EMPLOYEES	239

NGM Biopharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for NGM Biopharmaceuticals Inc? What does NGM stand for in stocks?

NGM is the stock ticker symbol of NGM Biopharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NGM Biopharmaceuticals Inc (NGM)?

As of Mon Apr 08 2024, market cap of NGM Biopharmaceuticals Inc is 128.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NGM stock?

You can check NGM's fair value in chart for subscribers.

What is the fair value of NGM stock?

You can check NGM's fair value in chart for subscribers. The fair value of NGM Biopharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NGM Biopharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NGM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NGM Biopharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether NGM is over valued or under valued. Whether NGM Biopharmaceuticals Inc is cheap or expensive depends on the assumptions which impact NGM Biopharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NGM.

What is NGM Biopharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 08 2024, NGM's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 29.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NGM PE ratio will change depending on the future growth rate expectations of investors.